Hyperion DeFi Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw 87% adjusted gross profit growth, driven by diversified DeFi strategies and early partnerships on Hyperliquid. Despite HYPE price volatility impacting treasury value, business lines ramped, and 2026 guidance calls for 4x profit growth and positive cash flow.
-
Q3 2025 marked a successful transformation to a digital asset treasury model, with record net income, strong DeFi revenue growth, and innovative partnerships driving results. Guidance calls for accelerating revenue and positive cash flow in 2026, supported by robust capital and expanding validator operations.
-
Rebranded and pivoted to a crypto treasury strategy, acquiring 1.5M HYPE tokens via $50M financing. Q2 net loss narrowed to $8.8M, with R&D costs down 85% and cash up to $7.5M. Focus remains on maximizing HYPE returns and advancing Optejet device.
-
Hyperion DeFi Inc. has transformed into a DeFi-focused company, building a substantial HYPE token treasury and validator presence on Hyperliquid. The company leverages partnerships, liquid staking, and innovative strategies to generate yield and support ecosystem growth, while maintaining a conservative, long-term approach to capital and risk.
Fiscal Year 2024
-
Q3 2024 saw continued net losses as commercialization of MydCombi and clobetasol ramped up, with strong physician interest and positive feedback. Key pipeline milestones are approaching, including a pivotal Phase III readout for MicroPine, and new partnerships expand the dry eye portfolio.
-
Q2 2024 saw expanded product initiatives, including three dry eye collaborations and two FDA-approved products, with MicroPine nearing pivotal phase III data. Net loss increased due to higher R&D and one-time costs, while commercial launches for clobetasol and Mydcombi are on track. Cash runway extends through year-end, with additional capital being pursued.